Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Share-based Compensation (2016 - 2025)

Catalyst Pharmaceuticals' Share-based Compensation history spans 16 years, with the latest figure at $5.7 million for Q4 2025.

  • For Q4 2025, Share-based Compensation rose 9.48% year-over-year to $5.7 million; the TTM value through Dec 2025 reached $24.8 million, up 11.36%, while the annual FY2025 figure was $24.8 million, 11.36% up from the prior year.
  • Share-based Compensation reached $5.7 million in Q4 2025 per CPRX's latest filing, roughly flat from $5.7 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $8.2 million in Q1 2024 to a low of $1.5 million in Q4 2021.
  • Average Share-based Compensation over 5 years is $3.8 million, with a median of $3.6 million recorded in 2023.
  • Peak YoY movement for Share-based Compensation: surged 185.2% in 2024, then dropped 29.07% in 2025.
  • A 5-year view of Share-based Compensation shows it stood at $1.5 million in 2021, then soared by 30.84% to $1.9 million in 2022, then skyrocketed by 120.66% to $4.2 million in 2023, then grew by 21.67% to $5.2 million in 2024, then rose by 9.48% to $5.7 million in 2025.
  • Per Business Quant, the three most recent readings for CPRX's Share-based Compensation are $5.7 million (Q4 2025), $5.7 million (Q3 2025), and $7.6 million (Q2 2025).